Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma

Inclusion Criteria: * At least 18 years old and capable of giving informed consent. * Patient has radiological evidence of RCC consisting of: CT scan with stage T2, T3, T3a, T4, or any stage T with N1/2 and/or metastatic disease. * Patient is already having a nephrectomy. * Adequate cardiac function as assessed by electrocardiogram (ECG). * Patient is will to have a kidney biopsy at baseline/screening. * Patient has scored a 0 or 1 on the ECOG. * Patient is negative for HIV, Hepatitis B, Hepatitis C * If patient is a woman of child-bearing potential, they have to have a negative pregnancy test. Exclusion Criteria: * Patient has stage T1 disease without metastases. * Patient has abnormal laboratory values at screening within the following ranges: * Absolute neutrophil count ≤1.5 x 10(9)/L; Platelet count ≤ 100 x 10(9)/L * Leukocyte count ≤ 3 x 10(9)/L; Hemoglobin ≤ 80 g/L * Serum creatinine ≥ 2.0 x the upper normal limit (UNL) * Total bilirubin ≤ 1.5 x UNL; AST and ALT ≤ 3.0 x UNL * Fasting serum cholesterol ≤ 9.0 mmol/L * Fasting serum triglycerides ≤ 5.0 mmol/L * Patients with a known hyper-sensitivity to Temsirolimus. * Other currently active malignancies. * Currently taking any medications known to interfere with the metabolism of Temsirolimus. * Patients receiving anticoagulation with warfarin. * Patients with a history of pulmonary hypertension or interstitial lung disease. * Unstable angina as judged by the primary investigator, or any recent MI in the last 180 days.